|
Abstract Objective:To investigate the expression characteristics of nuclear transcription factor GATA6 in endometrial carcinoma tissue, and to analyze the relationship between GATA6 expression and clinicopathological parameters or prognosis of patients with endometrial carcinoma. Methods: Immunohistochemistry was used to detect the expression of GATA6 in specimens of 82 patients with endometrial carcinoma, specimen of 60 patients with atypical intimal hyperplasia, and 50 specimens of normal endometrium. The GATA6 expression differences were compared among the threen groups, and the relationship between GATA6 expression and clinicopathological parameters or prognosis of patients was analyzed. Results: The positive expression rates of GATA6 in endometrial carcinoma tissue, atypical endometrial hyperplasia tissue, and normal endometrium tissue were 63.4%, 18.3%, and 6.0%, respectively, which had statistically significant different (P<0.05). The expression of GATA6 was not associated with the pathological type of endometrial carcinoma (P>0.05). It was associated with TNM stage, differentiation degree, myometrial infiltration depth and lymph node metastasis (P<0.05). The 3-year survival rate of patients with GATA6 low expression was 92.3%, and the median survival time was 40 months. The 3-year survival rate of patients with GATA6 high expression was 54.7%, and the median survival time was 20 months, which had statistically significant different between the patients with GATA6 high expression and GATA6 low expression (P<0.05). Conclusions: GATA6 has highly expression in endometrial carcinoma tissue, and it is associated with invasiveness and poor prognosis of patients with endometrial carcinoma.
|
|
|
|
|
|
